Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women

References

• White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57(12):5792–5807.
   Google Scholar
• Davis TM. Pharmacokinetic studies of antimalarials: recent developments. Expert Rev Clin Pharmacol. 2016;9(3):341–343.
   Google Scholar
• D’Alessandro U, Hill J, Tarning J, et al. **Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018;18(4):e133–e46.
   Google Scholar
• Mosha D, Guidi M, Mwingira F, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58(8):4583–4592.
   Google Scholar
• Illamola SM, Bucci-Rechtweg C, Costantine MM, et al. Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. Br J Clin Pharmacol. 2018;84(2):215–222.
   Google Scholar
• Lohy Das J, Rulisa S, de Vries PJ, et al. Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in Rwandese pregnant women treated for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2018;62(10):e00518.
   Google Scholar
• Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13(11):e1002160.
   Google Scholar
• Soma-Pillay P, Nelson-Piercy C, Tolppanen H, et al. Physiological changes in pregnancy. Cardiovasc J Africa. 2016;27(2):89–94.
   Google Scholar
• Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6(6):689–699.
   Google Scholar
• Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33(5):328–343.
   Google Scholar
• Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–121.
   Google Scholar
• Tarning J, Kloprogge F, Piola P, et al. Population pharmacokinetics of artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J. 2012;11:293.
   Google Scholar
• de Kock M, Tarning J, Barnes KI, et al. Response to “Lactation status and studies of pyrimethamine pharmacokinetics in pregnancy. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):731.
   Google Scholar
• Salman S, TME D. Regarding “Lactation status and studies of pyrimethamine pharmacokinetics in pregnancy. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):730.
   Google Scholar
• Rogerson SJ. **Unger HW. Prevention and control of malaria in pregnancy - new threats, new opportunities? Expert Rev Anti Infect Ther. 2017;15(4):361–375.
   Google Scholar
• Garner P, Gulmezoglu AM. Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev. 2006;4:CD000169.
   Google Scholar
• White NJ. *Intermittent presumptive treatment for malaria. PLoS Med. 2005;2(1):e3.
   Google Scholar
• World Health Organization. WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). Geneva: World Health Organization; 2014.
   Google Scholar
• Arinaitwe E, Ades V, Walakira A, et al. Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda. PloS One. 2013;8(9):e73073.
   Google Scholar
• Ojurongbe O, Nguetse CN, Fayemiwo SA, et al. High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine. Pathog Glob Health. 2018:1–7.
   Google Scholar
• Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185(3):380–388.
   Google Scholar
• Braun V, Rempis E, Schnack A, et al. Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda. Malar J. 2015;14:372.
   Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015.
   Google Scholar
• Pekyi D, Ampromfi AA, Tinto H, et al. Four artemisinin-based treatments in African pregnant women with malaria. Malawi Med J. 2016;28(3):139–149.
   Google Scholar
• Pekyi D, Ampromfi AA, Tinto H, et al. *Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016;374(10):913–927.
   Google Scholar
• Nambozi M, Tinto H, Mwapasa V, et al. Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study. Malar J. 2019;18(1):105.
   Google Scholar
• McGready R, Keo NK, Villegas L, et al. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R Soc Trop Med Hyg. 2003;97(5):592–594.
   Google Scholar
• Mayer RC, Tan KR, Gutman JR. Safety of atovaquone-proguanil during pregnancy. J Travel Med. 2019;26(4):tay138.
   Google Scholar
• Saito M, Gilder ME, McGready R, et al. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018;17(11):1129–1144.
   Google Scholar
• Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malar J. 2015;14:461.
   Google Scholar
• Dellicour S, Sevene E, McGready R, et al. *First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. PLoS Med. 2017;14(5):e1002290.
   Google Scholar
• Moore KA, Simpson JA, Paw MK, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis. 2016;16(5):576–583.
   Google Scholar
• WorldWide Antimalarial Resistance Network Lumefantrine PKPDSG. Artemether-lumefantrine treatment of uncomplicated. Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13:227.
   Google Scholar
• Burger RJ, Visser BJ, Grobusch MP, et al. The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review. Malar J. 2016;15:99.
   Google Scholar
• McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62(12):1021–1031.
   Google Scholar
• Tarning J, Kloprogge F, Dhorda M, et al. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Antimicrob Agents Chemother. 2013;57(10):5096–5103.
   Google Scholar
• de Kock M, Tarning J, Workman L, et al. Pharmacokinetics of sulfadoxine and pyrimethamine for intermittent preventive treatment of malaria during pregnancy and after delivery. CPT Pharmacometrics Syst Pharmacol. 2017;6(7):430–438.
   Google Scholar
• Karunajeewa HA, Salman S, Mueller I, et al. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother. 2009;53(10):4368–4376.
   Google Scholar
• Odongo CO, Bisaso KR, Ntale M, et al. Trimester-specific population pharmacokinetics and other correlates of variability in sulphadoxine-pyrimethamine disposition among Ugandan pregnant women. Drugs R D. 2015;15(4):351–362.
   Google Scholar
• Salman S, Baiwog F, Page-Sharp M, et al. Optimal antimalarial dose regimens for sulfadoxine-pyrimethamine with or without azithromycin in pregnancy based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 2017;61(5):e02291–16.
   Google Scholar
• Kloprogge F, McGready R, Phyo AP, et al. Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Br J Clin Pharmacol. 2015;80(4):642–653.
   Google Scholar
• McGready R, Stepniewska K, Ward SA, et al. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62(5):367–371.
   Google Scholar
• McGready R, Phyo AP, Rijken MJ, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol. 2012;73(3):467–477.
   Google Scholar
• Onyamboko MA, Hoglund RM, Lee SJ, et al. A randomised controlled trial of 3 versus 5 days artemether-lumefantrine regimen for uncomplicated Plasmodium falciparum treatment in pregnancy in Africa. Antimicrob Agents Chemother. 2020;64(3):e01140–19.
   Google Scholar
• Morris K. Filling the gaps to tackle malaria in pregnancy. Lancet Infect Dis. 2011;11(3):167–168.
   Google Scholar
• Valea I, Tinto H, Traore-Coulibaly M, et al. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. J Antimicrob Chemother. 2014;69(9):2499–2507.
   Google Scholar
• Benjamin JM, Moore BR, Salman S, et al. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother. 2015;59(7):4260–4271.
   Google Scholar
• Rijken MJ, McGready R, Phyo AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2011;55(12):5500–5506.
   Google Scholar
• Birgersson S, Valea I, Tinto H, et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Res. 2020;4:45.
   Google Scholar
• Kouakou YI, Tod M, Leboucher G, et al. Systematic review of artesunate pharmacokinetics: implication for treatment of resistant malaria. Int J Infect Dis. 2019;89:30–44.
   Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, et al. National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–639.
   Google Scholar
• Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab. 2009;10(5):520–529.
   Google Scholar
• Morris CA, Onyamboko MA, Capparelli E, et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J. 2011;10:114.
   Google Scholar
• Nyunt MM, Nguyen VK, Kajubi R, et al. Artemether-lumefantrine pharmacokinetics and clinical response are minimally altered in pregnant Ugandan women treated for uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2015;60(3):1274–1282.
   Google Scholar
• Kajubi R, Huang L, Jagannathan P, et al. Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention. Clin Pharmacol Ther. 2017;102(3):520–528.
   Google Scholar
• World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Geneva: Switzerland; 2018.
   Google Scholar
• Natureeba P, Kakuru A, Muhindo M, et al. Intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria among HIV-infected pregnant women. J Infect Dis. 2017;216(1):29–35.
   Google Scholar
• Lohy Das J, Dondorp AM, Nosten F, et al. Population pharmacokinetic and pharmacodynamic modeling of artemisinin resistance in Southeast Asia. AAPS. 2017;19(6):1842–1854.
   Google Scholar
• Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41(1):34–48.
   Google Scholar
• Tarning J, McGready R, Lindegardh N, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009;53(9):3837–3846.
   Google Scholar
• Kloprogge F, Piola P, Dhorda M, et al. Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. CPT Pharmacometrics Syst Pharmacol. 2013;2:e83.
   Google Scholar
• Kloprogge F, McGready R, Hanpithakpong W, Blessborn D, Day NP, White NJ, et al. Lumefantrine and desbutyl-lumefantrine population pharmacokinetic-pharmacodynamic relationships in pregnant women with uncomplicated Plasmodium falciparum malaria on the Thailand-Myanmar border. Antimicrob Agents Chemother. 2015;59(10):6375–6384.
   Google Scholar
• Nyunt MM, Nguyen VK, Kajubi R, et al. Artemether-lumefantrine pharmacokinetics and clinical response is minimally altered in Ugandan pregnant women treated for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2015;60(3):1274–1282.
   Google Scholar
• Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2010;10(11):762–769.
   Google Scholar
• Kloprogge F, Workman L, Borrmann S, et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018;15(6):e1002579.
   Google Scholar
• Mutagonda RF, Kamuhabwa AA, Minzi OM, et al. Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women. Malar J. 2016;15(1):278.
   Google Scholar
• Olafuyi O, Coleman M, Badhan RKS. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy. Biopharm Drug Dispos. 2017;38(8):464–478.
   Google Scholar
• Mutagonda RF, Minzi OMS, Massawe SN, et al. Pregnancy and CYP3A5 genotype affect day 7 plasma lumefantrine concentrations. Drug Metab Disposition. 2019;47(12):1415–1424.
   Google Scholar
• McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5(12):e253.
   Google Scholar
• Mutagonda RF, Kamuhabwa AAR, Minzi OMS, et al. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017;16(1):267.
   Google Scholar
• Hughes E, Mwebaza N, Huang L, et al. Efavirenz-based antiretroviral therapy reduces artemether-lumefantrine exposure for malaria treatment in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2020;83(2):140–147.
   Google Scholar
• Adegbola A, Abutaima R, Olagunju A, et al. Effect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria coinfection. Antimicrob Agents Chemother. 2018;62(10):e01252–18.
   Google Scholar
• Adam I, Tarning J, Lindegardh N, et al. Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2012;87(1):35–40.
   Google Scholar
• Hoglund RM, Adam I, Hanpithakpong W, Ashton M, Lindegardh N, Day NP, et al. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J. 2012;11:398.
   Google Scholar
• Moore BR, Benjamin JM, Auyeung SO, et al. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol. 2016;82(1):199–212.
   Google Scholar
• Benjamin JM, Moore BR, Salman S, et al. Population pharmacokinetics, tolerability and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and non-pregnant Papua New Guinean women. Antimicrob Agents Chemo. 2015;59(7):4260–4271.
   Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. Third ed. Geneva: World Health Organization; 2015.
   Google Scholar
• Savic RM, Jagannathan P, Kajubi R, et al. Intermittent preventive treatment for malaria in pregnancy: optimization of target concentrations of dihydroartemisinin-piperaquine. Clin Infect Dis. 2018;67(7):1079–1088.
   Google Scholar
• Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin–piperaquine for the prevention of malaria in pregnancy. New Eng J Med. 2016;374(10):928–939.
   Google Scholar
• Wallender E, Zhang N, Conrad M, et al. Modeling prevention of malaria and selection of drug resistance with different dosing schedules of dihydroartemisinin-piperaquine preventive therapy during pregnancy in Uganda. Antimicrob Agents Chemother. 2019;63(2):e01393–18.
   Google Scholar
• Wallender E, Vucicevic K, Jagannathan P, et al. Predicting optimal dihydroartemisinin-piperaquine regimens to prevent malaria during pregnancy for Human Immunodeficiency Virus-infected women receiving efavirenz. J Infect Dis. 2018;217(6):964–972.
   Google Scholar
• Moore BR, Salman S, Benjamin J, et al. Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. Antimicrob Agents Chemother. 2015;59(7):4272–4278.
   Google Scholar
• Na Bangchang K, Davis TM, Looareesuwan S, et al. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg. 1994;88(3):321–323.
   Google Scholar
• Nosten F, Karbwang J, White NJ, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol. 1990;30(1):79–85.
   Google Scholar
• Ramharter M, Schwab M, Mombo-Ngoma G, et al. Population pharmacokinetics of mefloquine intermittent preventive treatment for malaria in pregnancy in Gabon. Antimicrob Agents Chemother. 2019;63(2):e01113–18.
   Google Scholar
• Green M, Otieno K, Katana A, et al. Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. Malar J. 2016;15:7.
   Google Scholar
• Haaland RE, Otieno K, Martin A, et al. Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy. AIDS Res Hum Retroviruses. 2018;34(11):912–915.
   Google Scholar
• Rijken MJ, McGready R, Jullien V, et al. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob Agents Chemother. 2011;55(9):4338–4342.
   Google Scholar
• Tarning J, Chotsiri P, Jullien V, et al. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother. 2012;56(11):5764–5773.
   Google Scholar
• Kloprogge F, Jullien V, Piola P, et al. Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. J Antimicrob Chemother. 2014;69(11):3033–3040.
   Google Scholar
• Mirghani RA, Elagib I, Elghazali G, et al. Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. Eur J Clin Pharmacol. 2010;66(12):1229–1234.
   Google Scholar
• Abdelrahim II, Adam I, Elghazali G, et al. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. J Clinical Pharm Ther. 2007;32(1):15–19.
   Google Scholar
• Kayentao K, Guirou EA, Doumbo OK, et al. Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection. Am J Trop Med Hyg. 2014;90(3):530–534.
   Google Scholar
• Salman S, Rogerson SJ, Kose K, et al. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob Agents Chemother. 2010;54(1):360–366.
   Google Scholar
• Salman S, Davis TM, Page-Sharp M, et al. Pharmacokinetics of transfer of azithromycin into the breast milk of African mothers. Antimicrob Agents Chemother. 2015;60(3):1592–1599.
   Google Scholar
• Phiri K, Kimani J, Mtove GA, et al. Parasitological clearance rates and drug concentrations of a fixed dose combination of azithromycin-chloroquine in asymptomatic pregnant women with Plasmodium falciparum parasitemia: an open-label, non-comparative study in sub-Saharan Africa. PloS One. 2016;11(11):e0165692.
   Google Scholar
• Kimani J, Phiri K, Kamiza S, et al. Efficacy and safety of azithromycin-chloroquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa: an open-label, randomized trial. PloS One. 2016;11(6):e0157045.
   Google Scholar
• Divala TH, Mungwira RG, Mawindo PM, et al. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. Lancet Infect Dis. 2018;18(10):1097–1107.
   Google Scholar
• Karunajeewa HA, Salman S, Mueller I, et al. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob Agents Chemother. 2010;54(3):1186–1192.
   Google Scholar
• Lee SJ, McGready R, Fernandez C, et al. Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol. 2008;64(10):987–992.
   Google Scholar
• Massele AY, Kilewo C, Aden Abdi Y, et al. Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy. Eur J Clin Pharmacol. 1997;52(4):299–305.
   Google Scholar
• Chukwuani MC, Bolaji OO, Onyeji CO, et al. Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy. Trop Med Int Health. 2004;9(5):601–605.
   Google Scholar
• Salman S, Baiwog F, Page-Sharp M, et al. Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. Int J Antimicrob Agents. 2017;50(4):542–551.
   Google Scholar
• Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512–519.
   Google Scholar
• Flanagan KL, Buckley-Sharp M, Doherty T, et al. Quinine levels revisited: the value of routine drug level monitoring for those on parenteral therapy. Acta Trop. 2006;97(2):233–237.
   Google Scholar
• Onyamboko MA, Meshnick SR, Fleckenstein L, et al. Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC. Malar J. 2011;10:49.
   Google Scholar
• Schalkwijk S, Greupink R, Burger D. Free drug concentrations in pregnancy: bound to measure unbound? Br J Clin Pharmacol. 2017;83(12):2595–2598.
   Google Scholar
• Francis J, Barnes KI, Workman L, et al. An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrob Agents Chemother. 2020;64(5):e02394–19.
   Google Scholar
• Walimbwa SI, Lamorde M, Waitt C, et al. Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother. 2019;63(2):e01310–18.
   Google Scholar
• Inzaule SC, Jordan MR, Cournil A, et al. Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. AIDS. 2019;33(11):1797–1799.
   Google Scholar
• Keshavarzi Arshadi A, Salem M, Collins J, et al. DeepMalaria: artificial intelligence driven discovery of potent antiplasmodials. Front Pharmacol. 2019;10:1526.
   Google Scholar
• Yuan Q, Wei Z, Guan X, et al. Toxicity prediction method based on multi-channel convolutional neural network. Molecules. 2019;24(18):3383.
   Google Scholar